HK1203052A1 - Nanoparticles with enhanced mucosal penetration or decreased inflammation - Google Patents
Nanoparticles with enhanced mucosal penetration or decreased inflammationInfo
- Publication number
- HK1203052A1 HK1203052A1 HK15103577.8A HK15103577A HK1203052A1 HK 1203052 A1 HK1203052 A1 HK 1203052A1 HK 15103577 A HK15103577 A HK 15103577A HK 1203052 A1 HK1203052 A1 HK 1203052A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- nanoparticles
- mucosal penetration
- decreased inflammation
- enhanced mucosal
- enhanced
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
- B82B3/00—Manufacture or treatment of nanostructures by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nanotechnology (AREA)
- Biomedical Technology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Reproductive Health (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Manufacturing & Machinery (AREA)
- Medical Informatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161570413P | 2011-12-14 | 2011-12-14 | |
US201161570405P | 2011-12-14 | 2011-12-14 | |
PCT/US2012/024344 WO2012109363A2 (fr) | 2011-02-08 | 2012-02-08 | Vecteurs géniques pénétrant le mucus |
PCT/US2012/069882 WO2013090804A2 (fr) | 2011-12-14 | 2012-12-14 | Nanoparticules présentant une pénétration mucosale accrue ou une inflammation diminuée |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1203052A1 true HK1203052A1 (en) | 2015-10-16 |
Family
ID=48613373
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15103577.8A HK1203052A1 (en) | 2011-12-14 | 2015-04-13 | Nanoparticles with enhanced mucosal penetration or decreased inflammation |
Country Status (11)
Country | Link |
---|---|
US (2) | US20140329913A1 (fr) |
EP (1) | EP2790733B1 (fr) |
JP (3) | JP6308679B2 (fr) |
KR (1) | KR20140135948A (fr) |
CN (1) | CN104105507B (fr) |
AU (2) | AU2012351994B2 (fr) |
BR (1) | BR112014014262A2 (fr) |
CA (1) | CA2859046C (fr) |
HK (1) | HK1203052A1 (fr) |
RU (1) | RU2631599C2 (fr) |
WO (1) | WO2013090804A2 (fr) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011106702A2 (fr) | 2010-02-25 | 2011-09-01 | The Johns Hopkins University | Délivrance prolongée d'agents thérapeutiques à un compartiment oculaire |
WO2012039979A2 (fr) | 2010-09-10 | 2012-03-29 | The Johns Hopkins University | Diffusion rapide de grosses nanoparticules polymères dans le cerveau de mammifères |
WO2012109363A2 (fr) | 2011-02-08 | 2012-08-16 | The Johns Hopkins University | Vecteurs géniques pénétrant le mucus |
EP2790733B1 (fr) * | 2011-12-14 | 2019-10-30 | The Johns Hopkins University | Nanoparticules présentant une pénétration mucosale accrue ou une inflammation diminuée |
CA2867381C (fr) | 2012-03-16 | 2016-09-20 | The Johns Hopkins University | Formulations a liberation controlee pour l'administration d'inhibiteurs du hif-1 |
CN104394891B (zh) | 2012-03-16 | 2019-04-16 | 约翰霍普金斯大学 | 用于递送活性剂的非线性多嵌段共聚物-药物结合物 |
KR102140989B1 (ko) | 2012-05-03 | 2020-08-04 | 칼라 파마슈티컬스, 인크. | 개선된 점막 수송을 나타내는 제약 나노입자 |
US9827191B2 (en) | 2012-05-03 | 2017-11-28 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
EP3808339A1 (fr) | 2012-05-03 | 2021-04-21 | Kala Pharmaceuticals, Inc. | Nanoparticles pharmaceutiques montrant du transport mucosale amélioré |
US11596599B2 (en) | 2012-05-03 | 2023-03-07 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
US9889208B2 (en) | 2012-05-04 | 2018-02-13 | The Johns Hopkins University | Lipid-based drug carriers for rapid penetration through mucus linings |
WO2014124006A1 (fr) | 2013-02-05 | 2014-08-14 | The Johns Hopkins University | Nanoparticules pour le suivi de l'imagerie par résonance magnétique et procédés de fabrication et d'utilisation associés |
JP6669499B2 (ja) | 2013-02-15 | 2020-03-18 | カラ ファーマシューティカルズ インコーポレイテッド | 治療用化合物 |
US9688688B2 (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof |
US9353123B2 (en) | 2013-02-20 | 2016-05-31 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
US20160129133A1 (en) * | 2013-06-24 | 2016-05-12 | Nexlmmune, Inc. | Compositions and methods for immunotherapy |
WO2015017506A2 (fr) * | 2013-07-30 | 2015-02-05 | Blend Therapeutics, Inc. | Diagnostic et procédés de traitement d'une maladie avec des nanoparticules |
US9890173B2 (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
CN106061261B (zh) | 2013-11-01 | 2018-04-24 | 卡拉制药公司 | 治疗化合物的结晶形式及其用途 |
US10335500B2 (en) | 2014-05-12 | 2019-07-02 | The Johns Hopkins University | Highly stable biodegradable gene vector platforms for overcoming biological barriers |
WO2016004290A1 (fr) | 2014-07-03 | 2016-01-07 | Bind Therapeutics, Inc. | Nanoparticules thérapeutiques ciblées et procédés pour les produire et les utiliser |
WO2016007647A1 (fr) | 2014-07-09 | 2016-01-14 | The Johns Hopkins University | Découverte d'inhibiteurs de la glutaminase et administration améliorée par des nanoparticules pour la thérapie anticancéreuse |
CN107278151A (zh) | 2014-12-15 | 2017-10-20 | 约翰霍普金斯大学 | 舒尼替尼制剂及其在治疗青光眼中的使用方法 |
EP3237003B1 (fr) | 2014-12-24 | 2021-08-11 | NexImmune, Inc | Compositions de nanoparticules et méthodes pour l'immunothérapie |
JP6846351B2 (ja) | 2015-01-27 | 2021-03-24 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 粘膜表面における活性薬剤の増強された輸送のための低張ヒドロゲル製剤 |
CN105412935B (zh) * | 2015-02-04 | 2019-02-19 | 四川大学 | 一种基于n-(2-羟丙基)甲基丙烯酰胺聚合物的纳米粒及其制备方法 |
CN104784116B (zh) * | 2015-04-15 | 2017-05-24 | 武汉诺贝药业有限公司 | 一种n‑乙酰半胱氨酸口服制剂 |
US20180139997A1 (en) * | 2015-06-15 | 2018-05-24 | Gexnano S.R.L. | Food supplement for use in a process of metabolic rebalancing |
AR106018A1 (es) | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos |
WO2017035408A1 (fr) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Composés pour le traitement de troubles immunitaires et inflammatoires |
JP2018536017A (ja) | 2015-09-22 | 2018-12-06 | グレイバグ ビジョン インコーポレイテッド | 眼障害の治療のための化合物及び組成物 |
CA3003733C (fr) | 2015-10-30 | 2021-04-20 | The Johns Hopkins University | Particules a poids moleculaire eleve penetrant dans le mucus et revetements denses |
WO2017083779A1 (fr) | 2015-11-12 | 2017-05-18 | Graybug Vision, Inc. | Aggrégation de microparticules pour un usage thérapeutique |
RU2018145364A (ru) | 2016-06-27 | 2020-07-28 | Ачиллион Фармасьютикалс, Инк. | Хиназолиновые и индольные соединения для лечения медицинских нарушений |
US10253036B2 (en) | 2016-09-08 | 2019-04-09 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
AU2017324716B2 (en) | 2016-09-08 | 2020-08-13 | KALA BIO, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
EP3509421A4 (fr) | 2016-09-08 | 2020-05-20 | Kala Pharmaceuticals, Inc. | Formes cristallines de composés thérapeutiques et leurs utilisations |
EP3295937A1 (fr) * | 2016-09-20 | 2018-03-21 | Centre National De La Recherche Scientifique | Promédicament nanoparticulaire |
WO2018169960A1 (fr) | 2017-03-17 | 2018-09-20 | The Johns Hopkins University | Formulations de nanoparticules pour une administration améliorée de médicament à la vessie |
EP3600324A4 (fr) | 2017-03-23 | 2020-12-09 | Graybug Vision, Inc. | Composés et compositions pour le traitement de troubles oculaires |
CN111201040A (zh) | 2017-05-10 | 2020-05-26 | 灰色视觉公司 | 用于医学疗法的缓释微粒及其悬浮液 |
EP3841086A4 (fr) | 2018-08-20 | 2022-07-27 | Achillion Pharmaceuticals, Inc. | Composés pharmaceutiques pour le traitement de troubles médicaux du facteur d du complément |
EP3866773A4 (fr) | 2018-10-16 | 2022-10-26 | Georgia State University Research Foundation, Inc. | Promédicaments de monoxyde de carbone pour le traitement de troubles médicaux |
US10420731B1 (en) * | 2019-01-18 | 2019-09-24 | King Saud University | Method of synthesizing lignin-based nanocompositions |
WO2021050568A1 (fr) * | 2019-09-09 | 2021-03-18 | Yale University | Nanoparticules pour absorption sélective de tissu ou cellulaire |
US20230074885A1 (en) * | 2020-02-05 | 2023-03-09 | The Johns Hopkins University | Bortezomib-loaded nanoparticles |
CN116916885A (zh) * | 2021-01-12 | 2023-10-20 | 罗利亚制药有限责任公司 | 用作注射型填充剂的多重黏度水包油组合物和胶原生长支架 |
CN112915916B (zh) * | 2021-01-29 | 2022-05-24 | 江南大学 | 一种pH刺激响应型胆汁盐Pickering复合乳化剂 |
CN114983976B (zh) * | 2022-06-23 | 2023-07-25 | 浙江工业大学 | 一种紫杉醇纳米制剂及其制备方法和应用 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU531759B2 (en) | 1978-04-17 | 1983-09-08 | Ici Ltd. | Electrostatic spraying |
GB8504253D0 (en) | 1985-02-19 | 1985-03-20 | Ici Plc | Electrostatic spraying apparatus |
US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
US5019400A (en) | 1989-05-01 | 1991-05-28 | Enzytech, Inc. | Very low temperature casting of controlled release microspheres |
US7052678B2 (en) | 1997-09-15 | 2006-05-30 | Massachusetts Institute Of Technology | Particles for inhalation having sustained release properties |
US6509323B1 (en) | 1998-07-01 | 2003-01-21 | California Institute Of Technology | Linear cyclodextrin copolymers |
US20040253243A1 (en) * | 2003-01-21 | 2004-12-16 | David Epstein | Aptamer therapeutics useful in ocular pharmacotherapy |
WO2004112696A2 (fr) * | 2003-05-20 | 2004-12-29 | Erimos Pharmaceutical Llp | Methodes et compositions pour distribuer des butanes catecholiques pour assurer le traitement de pathologies |
EP1713514B1 (fr) * | 2004-01-28 | 2021-11-24 | Johns Hopkins University | Medicaments et particules de transport de genes se depla ant rapidement a travers les barrieres muqueuses |
US8658608B2 (en) | 2005-11-23 | 2014-02-25 | Yale University | Modified triple-helix forming oligonucleotides for targeted mutagenesis |
WO2007074604A1 (fr) * | 2005-12-26 | 2007-07-05 | Ltt Bio-Pharma Co., Ltd. | Nanoparticule contenant une substance hydrosoluble, non peptidique, de faible poids moleculaire |
JP2008053276A (ja) | 2006-08-22 | 2008-03-06 | Nec Electronics Corp | 半導体装置の製造方法 |
CA2663003C (fr) * | 2006-09-08 | 2018-02-13 | Justin Hanes | Compositions et methodes destinees a ameliorer le transport a travers le mucus |
CN101678113B (zh) * | 2007-05-14 | 2012-05-30 | 日本株式会社Ltt生物医药 | 缓释性的含有带负电荷基团的低分子药物的纳米粒子 |
EP2106806A1 (fr) * | 2008-03-31 | 2009-10-07 | Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. | Nanoparticules pour la livraison ciblée d'agents actifs vers les poumons |
WO2010005721A2 (fr) * | 2008-06-16 | 2010-01-14 | Bind Biosciences, Inc. | Nanoparticules polymères pharmacologiquement chargées et leurs méthodes de fabrication et d’utilisation |
WO2011133803A1 (fr) | 2010-04-21 | 2011-10-27 | Helix Therapeutics, Inc. | Compositions et méthodes d'inactivation ciblée de récepteurs de surface cellulaire de vih |
WO2012061703A1 (fr) * | 2010-11-05 | 2012-05-10 | The Johns Hopkins University | Compositions et procédés visant à une réduction de la mucoadhérence |
EP2790733B1 (fr) * | 2011-12-14 | 2019-10-30 | The Johns Hopkins University | Nanoparticules présentant une pénétration mucosale accrue ou une inflammation diminuée |
KR101811917B1 (ko) * | 2012-01-19 | 2017-12-22 | 더 존스 홉킨스 유니버시티 | 점액 침투 강화를 나타내는 나노 입자 제형 |
CA3003733C (fr) * | 2015-10-30 | 2021-04-20 | The Johns Hopkins University | Particules a poids moleculaire eleve penetrant dans le mucus et revetements denses |
-
2012
- 2012-12-14 EP EP12820997.0A patent/EP2790733B1/fr active Active
- 2012-12-14 US US14/365,963 patent/US20140329913A1/en not_active Abandoned
- 2012-12-14 RU RU2014128578A patent/RU2631599C2/ru active
- 2012-12-14 AU AU2012351994A patent/AU2012351994B2/en active Active
- 2012-12-14 KR KR1020147019535A patent/KR20140135948A/ko not_active Application Discontinuation
- 2012-12-14 CN CN201280069271.1A patent/CN104105507B/zh active Active
- 2012-12-14 BR BR112014014262A patent/BR112014014262A2/pt not_active Application Discontinuation
- 2012-12-14 CA CA2859046A patent/CA2859046C/fr active Active
- 2012-12-14 JP JP2014547513A patent/JP6308679B2/ja active Active
- 2012-12-14 WO PCT/US2012/069882 patent/WO2013090804A2/fr active Application Filing
-
2015
- 2015-04-13 HK HK15103577.8A patent/HK1203052A1/xx unknown
-
2016
- 2016-02-03 AU AU2016200683A patent/AU2016200683B2/en active Active
- 2016-04-11 JP JP2016078766A patent/JP6590750B2/ja active Active
-
2018
- 2018-02-02 JP JP2018017235A patent/JP2018065882A/ja active Pending
-
2021
- 2021-02-24 US US17/184,087 patent/US20210196829A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2016200683B2 (en) | 2017-08-10 |
US20210196829A1 (en) | 2021-07-01 |
EP2790733A2 (fr) | 2014-10-22 |
KR20140135948A (ko) | 2014-11-27 |
BR112014014262A2 (pt) | 2017-06-13 |
WO2013090804A3 (fr) | 2013-08-22 |
AU2012351994A1 (en) | 2014-07-24 |
JP2018065882A (ja) | 2018-04-26 |
JP2016128522A (ja) | 2016-07-14 |
WO2013090804A2 (fr) | 2013-06-20 |
CN104105507B (zh) | 2020-03-24 |
AU2016200683A1 (en) | 2016-02-18 |
US20140329913A1 (en) | 2014-11-06 |
JP6308679B2 (ja) | 2018-04-11 |
EP2790733B1 (fr) | 2019-10-30 |
JP2015505855A (ja) | 2015-02-26 |
JP6590750B2 (ja) | 2019-10-16 |
CA2859046A1 (fr) | 2013-06-20 |
AU2012351994B2 (en) | 2015-11-05 |
CA2859046C (fr) | 2019-10-22 |
RU2014128578A (ru) | 2016-02-10 |
RU2631599C2 (ru) | 2017-09-25 |
CN104105507A (zh) | 2014-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1203052A1 (en) | Nanoparticles with enhanced mucosal penetration or decreased inflammation | |
HUS2100012I1 (hu) | 4-Imidazopiridazin-1-il-benzamidok és 4-imidazotriazin-1-il-benzamidok mint BTK-gátlók | |
HK1215380A1 (zh) | 增強粘膜滲透的納米粒子調配物 | |
HK1203474A1 (en) | Surface modified nanoparticles | |
EP2750662A4 (fr) | Nanoparticules ciblant l'apoptose | |
HK1192839A1 (en) | Amatoxin-conjugates with improved linkages | |
EP2747596A4 (fr) | Ensemble de rouleaux concave-convexe | |
GB201005601D0 (en) | Ecapsulated nanoparticles | |
PL2691443T3 (pl) | Sprzężone lipomery i ich zastosowania | |
EP2833926A4 (fr) | Nanoparticules neurophiles | |
ZA201205425B (en) | Treatment with vb-201 | |
ZA201402257B (en) | Tapered structure construction | |
GB201216930D0 (en) | Nanoparticles | |
PT2790739T (pt) | Nanopartículas e utilizações das mesmas | |
EP2867155A4 (fr) | Nanostructure comportant des côtés fonctionnellement différents | |
PT2829180T (pt) | Agente para aumento do teor em açúcar de frutos | |
ZA201409359B (en) | Egg-carton with window | |
GB201221113D0 (en) | Wind deflector | |
GB201209517D0 (en) | Nanoparticles | |
SI2492413T1 (sl) | Vrečast baldahin | |
ZA201406778B (en) | Crossbow | |
PL2474682T3 (pl) | Markiza | |
IL211389A0 (en) | Wind gybe | |
GB201216325D0 (en) | Fencing | |
PT2734522T (pt) | 4-imidazopiridazina-1-il-benzamidas e 4-imidazotriazin-1- il-benzamidas como inibidores de btk |